Ligand Pharma (LGND) outperforms via a high-margin royalty model and disciplined investing. Click here to read my most recent ...

Both have plenty to offer investors, but one has a better outlook.

LGM Pharma, a leading provider of tailored API sourcing, contract analytical testing, and CDMO services for the full drug ...

Seasoned life science investor, executive and board leader to support next phase of growth as BOOST Pharma advances BT-101, a promising and potentially disease-modifying therapy for osteogenesis ...

While Johnson & Johnson retains the top revenue rank across the major pharma companies, Eli Lilly last year established ...

On March 19, Barclays raised its price recommendation on Johnson & Johnson (NYSE:JNJ) to $234 from $217. It kept an Equal ...

Catalyst Pharmaceuticals (NASDAQ:CPRX) highlighted continued growth in its rare disease portfolio and outlined efforts to expand patient identification and penetration for its lead product during a ...

Royalty Pharma reports Q1 2025 financials with 17% portfolio receipts growth, raising 2025 guidance to $2,975-$3,125 million. Royalty Pharma plc announced its financial results for the first quarter ...

After posting revenue increases for six straight years, including double-digit growth in 2021 and 2022, Merck KGaA took a hard fall last year, with its global sales declining by 6% to 21 billion euros ...

Rapid Micro Biosystems, Inc. sees strong FY25 revenue growth from Growth Direct placements, but losses persist. Click for ...

NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) will host an Investor Day in New York City today. Senior executives will provide an update on the company’s plans to ...

Bormioli Pharma, a global leader partnering with customers to provide comprehensive packaging solutions for injectable drugs, today announced robust growth in its North American business in 2022, with ...